(Amherst, NH) – The convergence of biological drug development and applied genetics is moving beyond traditional models of therapeutic drug administration and creating challenges for medical technologists. By targeting biologicals at the cellular level, researchers are attempting to establish a new generation of therapeutics that has the potential to approach the precision and accuracy envisioned ever since the commercial introduction of PCR.
Numerous programs and clinical trials are involved in the development of direct-to-cell delivery using a variety of vectors and techniques, but progress to date has been disappointing. Methods based on host systems such as viruses and hydrophobic formulations (liposomes) are highly API-specific, slowing development. Electroporation has been investigated extensively, but success has been hampered by the limitations of early generation devices that limited the ability to optimize protocols.
Recently, a new generation of electroporation devices has emerged and they’re generating interest by targeting a handful of highly-specific but potentially lucrative therapeutic targets that collectively represent a long-standing unmet market need. While the majority of current electroporation applications are in the research sector, the eventual commercialization of new treatments currently in the clinical trial phase is expected to create opportunities for sector participants.
Greystone’s analysis of the clinical markets and applications for electroporation of therapeutic biologicals includes an assessment of commercial devices and design factors, an analysis of key partnerships that are refining treatment protocols, and forecasts of probable demand within targeted therapeutic market segments. These findings are included in a new publication – Electroporation: Evolving Opportunities for Delivering Targeted Biologicals. The report also examines the key players in this segment, regulatory and economic factors, and the dynamics of patient care that will affect market development.
More information is available at www.greystoneassociates.org .
About Greystone
Greystone Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.
Contact:
Mark Smith
Voice: 603-595-4340
Fax: 603-804-0466
www.greystoneassociates.org
Source: Greystone Associates
